Osteosarcoma metastasis: prospective role of ezrin

详细信息    查看全文

• 作者：Yuanjin Zhang (1)
  Ling Zhang (1)
  Guofu Zhang (1)
  Songbai Li (1)
  Jun Duan (1)
  Jie Cheng (1)
  Guozhen Ding (1)
  Chibing Zhou (1)
  Jie Zhang (2)
  Pengcheng Luo (2)
  Dongbing Cai (2)
  Lianghong Kuang (2)
  Yichun Zhou (2)
  Liqun Tong (2)
  Xiangdong Yu (2)
  Lifang Zhang (2)
  Lijun Xu (2)
  Li Yu (2)
  Xiaomei Shi (2)
  Aihong Ke (2)
  
• 关键词：Ezrin ; Osteosarcoma ; Pathophysiology of osteosarcoma ; Metastatic progression ; Bone sarcoma
• 刊名：Tumor Biology
• 出版年：2014
• 出版时间：June 2014
• 年：2014
• 卷：35
• 期：6
• 页码：5055-5059
• 全文大小：
• 参考文献：1. Damron TA, Ward WG, Stewart A. Osteosarcoma, chrondrosarcoma, and Ewing’s sarcoma. National Cancer Data Base Report. Clin Orthop Relat Res. 2007;459:40-. CrossRef
  2. Gurney JG, Swensen AR, Bulterys M. Malignant bone tumors. In: Ries LA, Smith MA, Gurney JG, et al., editors. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-995 (Pub #99-4649). Bethesda, MD: SEER program, National Cancer Institute; 1999. p. 99-10.
  3. Marcove RC, Mike V, Hajack JV, Levin AG, Hutter RV. Osteogenic sarcoma under the age of twenty-one. A review of one hundred and forty-five operative cases. J Bone Joint Surg. 1970;52:411-3.
  4. McKenna RJ, Schwinn CP, Soonh KY, Higinbotham N. Sarcomata of osteogenic series (osteosarcoma, fibrosarcoma, chondrosarcoma, parosteal osteosarcoma, and sarcomata arising in abnormal bone): an analysis of 552 cases. J Bone Joint Surg. 1966;48-A:1-6.
  5. Wittig JC, Bickels J, Priebat D, Jelinek J, Kellar-Graney K, Shmookler B, et al. Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician. 2002;65(1123-132):1135-.
  6. Bianco P, Riminucci M, Gronthos S, Robey P. Bone marrow stromal cells: nature, biology and potential applications. Stem Cells. 2001;19:180-2. CrossRef
  7. Bickels J, Jelinek BM, Shmookler BM, Neff RS, Malawar MM. Biopsy of musculoskeletal tumors. Current concepts. Clin Orthop Relat Res. 1999;368:212-.
  8. Huth JF, Eilber FR. Patterns of recurrence after resection of osteosarcoma of the extremity. Strategies for treatment of metastases. Arch Surg. 1989;124:122-. CrossRef
  9. Meyers PA, Heller G, Healey JH, Huvos A, Applewhite A, Sun M, et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol. 1993;11:449-3.
  10. Rubert CK, Malawer MM, Kellar KL. Modular endoprosthetic replacement of the proximal humerus: indications, surgical technique, and results. Semin Arthroplast. 1999;10:142-3.
  11. Malawer MM, Chou LB. Prosthetic survival and clinical results with use of large segment replacements in the treatment of high-grade bone sarcomas. J Bone Joint Surg. 1995;77:1154-5.
  12. Bacci G, Picci P, Briccoli A, Avella M, Ferrari S, Femino FP, et al. Osteosarcoma of the extremity metastatic at presentation: results achieved in 26 patients treated with combined therapy (primary chemotherapy followed by simultaneous resection of the primary and metastatic lesions). Tumori. 1992;78:200-.
  13. Bohndorf K, Reiser M, Lochner B, Feaux de Lacroix W, Steinbrich W. Magnetic resonance imaging of primary tumours and tumour-like lesions of bone. Skelet Radiol. 1986;15:511-. CrossRef
  14. Sundaram M, McGuire MH, Herbold DR. Magnetic resonance imaging of osteosarcoma. Skelet Radiol. 1987;16:23-. CrossRef
  15. Belli L, Scholl S, Livartowski A, Ashby M, Palangie T, Levasseur P, et al. Resection of pulmonary metastases in osteosarcoma. A retrospective analysis of 44 patients. Cancer. 1989;63:2546-0. CrossRef
  16. Enneking W, Spanier S, Goodman M. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop. 1980;153:106-0.
  17. Mialou V, Philip T, Kalifa C, Perol D, Gentet JC, Marec-Berard P, et al. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome—the French pediatric experience. Cancer. 2005;104:1100-. CrossRef
  18. Khanna C, Khan J, Nguyen P, et al. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res. 2001;61:3750-.
  19. Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol. 2002;3:586-9. CrossRef
  20. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004;10:182-. CrossRef
  21. Tsukita S, Yonemura S. ERM family: from cytoskeleton to signal transduction. Curr Opin Cell Biol. 1997;9:70-. CrossRef
  22. Curto M, McClatchey AI. Ezrin a metastatic determinant? Cancer Cell. 2004;5:113-. CrossRef
  23. McClatchey AI. Merlin and ERM proteins: unappreciated roles in cancer development? Nat Rev Cancer. 2003;3:877-2. CrossRef
  24. Yu Y, Khan J, Khanna C, et al. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med. 2004;10:175-1. CrossRef
  25. Gautreau A, Poullet P, Louvard D, Arpin M. Ezrin, a plasma membrane microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A. 1999;96:7300-. CrossRef
  26. Ward Y, Wang W, Woodhouse E, Linnoila I, Liotta L, Kelly K. Signal pathways which promote invasion and metastasis: critical and distinct contributions of extracellular signal-regulated kinase and Ral-specific guanine exchange factor pathways. Mol Cell Biol. 2001;21:5958-9. CrossRef
  27. Fukaya Y, Ishiguro N, Senga T, et al. A role for PI3K-Akt signaling in pulmonary metastatic nodule formation of the osteosarcoma cell line, LM8. Oncol Rep. 2005;14:847-2.
  28. Martin TA, Harrison G, Mansel RE, Jiang WG. The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol. 2003;46:165-6. CrossRef
  29. Peng TS, Qiu JS, Wu HX, Liang HZ, Luo CQ. Expressions of CD44s, MMP-9, and Ki-67: possible association with invasion, metastasis, and recurrence of osteosarcoma. Ai Zheng. 2002;21:745-0.
  30. Crepaldi T, Gautreau A, Comoglio PM, Louvard D, Arpin M. Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells. J Cell Biol. 1997;138:423-4. CrossRef
  31. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003;22:309-5. CrossRef
  32. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 2002;16:3074-6. CrossRef
  33. Pujuguet P, Del Maestro L, Gautreau A, Louvard D, Arpin M. Ezrin regulates E-cadherin-dependent adherens junction assembly through Rac1 activation. Mol Biol Cell. 2003;14:2181-1. CrossRef
  34. Tsukita S, Oishi K, Sato N, Sagara J, Kawai A, Tsukita S. ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J Cell Biol. 1994;126:391-01. CrossRef
  35. Xu Y, Yu Q. E-cadherin negatively regulates CD44-hyaluronan interaction and CD44-mediated tumor invasion and branching morphogenesis. J Biol Chem. 2003;278:8661-. CrossRef
  36. Vo HP, Lee MK, Crowe DL. Α2β1 integrin signaling via the mitogen activated protein kinase pathway modulates retinoic acid-dependent tumor cell invasion and transcriptional downregulation of matrix metalloproteinase 9 activity. Int J Oncol. 1998;13:1127-4.
  37. Hunter KW. Ezrin, a key component in tumor metastasis. Trends Mol Med. 2004;10:201-. CrossRef
  38. Park HR, Jung WW, Bacchini P, Bertoni F, Kim YW, Park YK. Ezrin in osteosarcoma: comparison between conventional high-grade and central low-grade osteosarcoma. Pathol Res Pract. 2006;202:509-5. CrossRef
  39. Weng WH, Ahlén J, Astr?m K, Lui WO, Larsson C. Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res. 2005;11:6198-04. CrossRef
  40. Wan X, Mendoza A, Khanna C, Helman L. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res. 2005;65:2406-1. CrossRef
  41. Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, Schreiber SL. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature. 1995;377:441-. CrossRef
  42. Brown EJ, Schreiber SL. A signaling pathway to translational control. Cell. 1996;86:517-0. CrossRef
  43. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8:128-5. CrossRef
  
• 作者单位：Yuanjin Zhang (1)
  Ling Zhang (1)
  Guofu Zhang (1)
  Songbai Li (1)
  Jun Duan (1)
  Jie Cheng (1)
  Guozhen Ding (1)
  Chibing Zhou (1)
  Jie Zhang (2)
  Pengcheng Luo (2)
  Dongbing Cai (2)
  Lianghong Kuang (2)
  Yichun Zhou (2)
  Liqun Tong (2)
  Xiangdong Yu (2)
  Lifang Zhang (2)
  Lijun Xu (2)
  Li Yu (2)
  Xiaomei Shi (2)
  Aihong Ke (2)
  
  1. Department of Orthopedics, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, No. 141 Tianjin Road, Huangshi City, 435000, Hubei Province, China
  2. Hubei Key Laboratory of Kidney Disease Pathogenesis and Intervention, Huangshi City, Hubei Province, China
  
• ISSN：1423-0380

文摘

Osteosarcoma is the most commonly diagnosed primary malignant bone tumor, with similar global incidence rate across childhood and adolescence. Patients with localized disease have a 5-year survival period of 80?%; however, the prognosis is poor in those with metastatic osteosarcoma. The origin of the primary tumor is most frequently the metaphyseal (actively growing) regions of the distal femur, proximal tibia, and proximal humerus, although the tumor can develop in any bone, and the most likely sites for metastasis are the lungs and bone. Ezrin is a member of the ezrin-radixin-moesin (ERM) family of proteins that functions as a cross-linker between the actin cytoskeleton and the plasma membrane, and ezrin also plays a positive role in maintaining cell shape and polarity and facilitates membrane-trafficking pathways, cell migration, cell signaling, growth regulation, and differentiation. There is strong evidence to suggest that ezrin is necessary for osteosarcoma metastasis. The objective of the current review is to summarize the know-how about metastatic progression in osteosarcoma, with a focus on ezrin. Despite the promise that preliminary studies on ezrin have shown, there is a great need to further analyze the role of ezrin in osteosarcoma metastasis and to determine its usefulness as a biomarker for the disease.